Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 2/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372446 | 0.84 | KCNQ3 (0.36) | KCNQ3KCNQ2KCNE1KCNQ1GRM4 | |
| SCHEMBL2370338 | 0.80 | LMNA (0.43) | KCNQ3KCNQ2KCNE1KCNQ1NAPRT | |
| SCHEMBL2370930 | 0.79 | NAPRT (0.38) | KCNQ3KCNQ2KCNE1KCNQ1NAPRT | |
| SCHEMBL28385587 | 0.72 | MEN1 (0.46) | PYGLPYGMLMNA | |
| SCHEMBL12682946 | 0.71 | MAP3K8 (0.40) | L3MBTL1 | |
| SCHEMBL2371199 | 0.71 | KDM4E (0.51) | LMNASCN8ASCN10A | |
| SCHEMBL1956720 | 0.71 | FFAR4 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1PYGL | |
| SCHEMBL11547858 | 0.68 | KCNQ3 (0.48) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL5364969 | 0.68 | PTGER4 (0.45) | — | |
| SCHEMBL30316008 | 0.68 | LCK (0.59) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | KCNQ3 1600/4885KCNQ2 1599/4885KCNE1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.